Lowest Price Guaranteed From USD 4,799
Published
August 2022
Pages
689
View Count
45507
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The viral vector manufacturing, non-viral vector manufacturing and gene therapy manufacturing market is estimated to be worth $651 million in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 14.0% during the forecast period. With the increasing number of cell and gene therapies being developed and launched for a wide range of therapeutic areas, these modalities are on their way to become one of the highest valued markets in the biopharmaceutical domain. In fact, in 2021, cell and gene therapy developers raised capital worth more than USD 20 billion, registering an increase of 19% from the amount raised in 2020 (~USD 17 billion). It is worth highlighting that, in February 2022, the USFDA approved second CAR-T therapy, CARVYKTI™, developed by Johnson and Johnson, which can be used for the treatment of relapsed or refractory multiple myeloma. Additionally, close to 1,500 clinical trials are being conducted, globally, for the evaluation of cell and gene therapies. Over time, it has been observed that the clinical success of these therapies relies on the design and type of gene delivery vector used (in therapy development and / or administration). At present, several innovator companies are actively engaged in the development / production of viral vectors and / or non-viral vectors for cell and gene therapies. In this context, it is worth mentioning that, over the past few years, multiple viral vector and non-viral vector based vaccine candidates have been developed against COVID-19 (caused by novel coronavirus, SARS-CoV-2) and oncological disorders; this is indicative of lucrative opportunities for companies that have the required capabilities for viral vector manufacturing and gene therapy manufacturing.
The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. Figure below provides a sample insight into the level of information covered in the report.
It is worth highlighting that several companies that have the required capabilities and facilities to manufacture vectors for both in-house requirements and offer contract services (primarily to ensure the optimum use of their resources and open up additional revenue generation opportunities) have emerged in this domain. Further, in order to produce more effective and affordable vectors, several stakeholders are integrating various novel technologies; these technologies are likely to improve the scalability and quality of the resultant therapy. In addition, this industry has also witnessed a significant increase in the partnership and expansion activities over the past few years, with several companies having been acquired by the larger firms. Given the growing demand for interventions that require genetic modification, the vector and gene therapy manufacturing market is poised to witness substantial growth in the foreseen future.
The “Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market (5th Edition) by Scale of Operation (Preclinical, Clinical and Commercial), Type of Vector (AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Therapeutic Area (Oncological Disorders, Rare Disorders, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musco-skeletal Disorders, Blood Disorders, Immunological Diseases, and Others), and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the rapidly growing market of vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies having in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
Segmentation
| Market Segments | Details | |
|
Forecast Period |
2022 – 2035 |
|
|
Scale of Operation |
Preclinical, Clinical, Commercial |
|
|
Type of Vector |
AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA, Other Vectors |
|
|
Application Area |
Gene Therapy, Cell Therapy, Vaccines |
|
|
Therapeutic Area |
Oncological Disorders, Rare Disorders, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musco-skeletal Disorders, Blood Disorders, Immunological Diseases, Others |
|
|
Geographical Regions |
North America, Europe, Asia-Pacific, MENA, Latin America, Rest of the World |
|
Amongst other elements, the report includes:
One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the vector and gene therapy manufacturing market, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies, anticipated growth in target patient population, existing price variations across different types of vectors, and the anticipated success of gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. In order to provide a detailed future outlook, our projections have been segmented on the basis of scale of operation (preclinical, clinical and commercial), type of vector (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), application area (gene therapy, cell therapy and vaccine), therapeutic area (oncological disorders, rare disorders, neurological disorders, sensory disorders, metabolic disorders, musco-skeletal disorders, blood disorders, immunological diseases, and others) and geographical region (North America, Europe, Asia Pacific, MENA, Latin America and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. Figure below provides an example insight
The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. For the purpose of the study, we invited over 300 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.
Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of the currently available gene delivery vehicles. The chapter also features the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market.
Chapter 4 provides a detailed overview of close to 150 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy / vaccine), location of manufacturing facilities, type of manufacturer (in-house and contract services), scale of operation (preclinical, clinical and commercial), type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).
Chapter 5 provides an overview of close to 70 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy / vaccine), location of plasmid DNA manufacturing facilities, type of manufacturer (in-house and contract services), scale of operation (preclinical, clinical and commercial) and application area (gene therapy, cell therapy, vaccine and others).
Chapter 6 provides an overview of close to 90 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, type of manufacturer (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).
Chapter 7 features an in-depth analysis of the technologies offered / developed by the companies engaged in this domain, based on the type of technology (viral vector manufacturing and non-viral vector manufacturing related platform), purpose of technology (vector manufacturing, gene delivery, product manufacturing, transduction / transfection, vector packaging and other), scale of operation (preclinical, clinical and commerical), type of vector involved (AAV, adenoviral, lentiviral, retroviral, non-viral and other viral vectors), application area (gene therapy, cell therapy, vaccine and others) and leading technology providers.
Chapter 8 presents a detailed competitiveness analysis of vector manufacturers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on its experience in this field), manufacturing strength (type of product manufactured, number of manufacturing facilities and number of application area), service strength (scale of operation, number of vectors manufactured and geographical reach) and company size (small, mid-sized and large).
Chapter 9 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in North America. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.
Chapter 10 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in Europe. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.
Chapter 11 features detailed profiles of some of the key players that have the capability to manufacture viral vectors / plasmid DNA in Asia-Pacific. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.
Chapter 12 features tabulated profiles of the other key players that have the capability to manufacture viral vectors / plasmid DNA. Each profile features an overview of the company, its financial performance (if available), information related to its manufacturing capabilities, and an informed future outlook.
Chapter 13 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015-2022, covering analysis based on parameters such as year of partnership, type of partnership(manufacturing agreement, product / technology licensing, product development, merger / acquisition, research and development agreement, process development / optimization, service alliance, production asset / facility acquisition, supply agreement and others), scale of operation (preclinical, clinical and commercial) and type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others) most active players (in terms of number of partnerships).
Chapter 14 features an elaborate discussion and analysis of the various expansions that have been undertaken, since 2015. Further, the expansion activities in this domain have been analyzed on the basis of year of expansion, type of expansion (new facility / plant establishment, facility expansion, technology installation / expansion, capacity expansion, service expansion and others), geographical location of the facility, type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others) and application area (gene therapy, cell therapy, vaccine and others).
Chapter 15 highlights potential strategic partners (vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength (clinical and preclinical). The analysis aims to provide the necessary inputs to the product developers, enabling them to make the right decisions to collaborate with industry stakeholders with relatively more initiatives in the domain.
Chapter 16 provides detailed information on other viral / non-viral vectors. These include alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus based vectors, Sendai virus based vectors, self-complementary vectors (improved versions of AAV), minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach) and chimeric vectors, that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development / manufacturing of some of these novel vectors.
Chapter 17 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of operation and type of manufacturer (fulfilling in-house requirement / contract service provider). In addition, it consists of a heat map of viral vector and plasmid DNA manufacturers based on the type of vector (AAV, adenoviral vector, lentiviral vector, retroviral vector and plasmid DNA) and type of organization (industry (small, mid-sized and large) and non-industry). The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (AAV, adenoviral, lentiviral, retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the geographical locations of key vector manufacturing hubs across different continents.
Chapter 18 highlights our views on the various factors that may be taken into consideration while pricing viral vectors / plasmid DNA. It features discussions on different pricing models / approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.
Chapter 19 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations by company size (small, mid-sized and large), scale of operation (clinical and commercial), type of vector (viral vector and plasmid DNA) and region (North America, Europe, Asia Pacific and the rest of the world).
Chapter 20 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.
Chapter 21 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of type of vector (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), application area (gene therapy, cell therapy and vaccine), therapeutic area (oncological disorders, rare disorders, neurological disorders, sensory disorders, metabolic disorders, musco-skeletal disorders, blood disorders, immunological diseases, and others), scale of operation (preclinical, clinical and commercial) and geography (North America, Europe, Asia Pacific, MENA, Latin America and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.
Chapter 22 highlights the qualitative analysis on the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of drug developers, bargaining power of vector and gene therapy manufacturers, threats of substitute technologies and rivalry among existing competitors.
Chapter 23 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.
Chapter 24 presents insights from the survey conducted on over 300 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.
Chapter 25 summarizes the entire report, highlighting various facts related to contemporary market trend and the likely evolution of the viral vector, non-viral vector and gene therapy manufacturing market.
Chapter 26 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Cedric Szpirer (Former Executive & Scientific Director, Delphi Genetics), Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Former Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Alain Lamproye (Former President of Biopharma Business Unit, Novasep), Joost van den Berg (Former Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes), Colin Lee Novick (Managing Director, CJ Partners), Semyon Rubinchik (Scientific Director, ACGT), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Former Marketing Manager, Plasmid Factory), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy), Nicolas Grandchamp (R&D Leader, GEG Tech), Géraldine Guérin-Peyrou (Director of Marketing and Technical Support, Polypus Transfection), Naiara Tejados, Head of Marketing and Technology Development, VIVEBiotech) and Jeffery Hung (Independent Consultant)
Chapter 27 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 28 is an appendix that provides the list of companies and organizations that have been mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Gene Transfer Techniques
3.3. Viral Vectors Used in Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus
3.5. Types of Non-Viral Vectors
3.5.1. Plasmid DNA
3.5.2. Liposomes, Lipoplexes and Polyplexes
3.5.3. Oligonucleotides
3.5.4. Other Non-Viral Vectors
3.6. Gene Delivery using Non-Viral Vectors
3.6.1. Biolistic Methods
3.6.2. Electroporation
3.6.3. Receptor Mediated Gene Delivery
3.6.4. Gene Activated Matrix (GAM)
3.7. Applications of Viral and Non-Viral Vectors
3.7.1. Type of Therapy
3.7.1.1. Cell and Gene Therapy
3.7.1.2. Vaccinology
3.8. Current / Ongoing Trends in Vector Development / Manufacturing
3.8.1. Vector Engineering
3.8.2. Cargo Engineering
3.9. Vector Manufacturing
3.9.1. Types of Vector Manufacturers
3.9.2. Viral Vector Manufacturing Processes
3.9.2.1 Vector Production
3.9.2.2. Adherent and Suspension Cultures
3.9.2.3. Unit Process Versus Multiple Parallel Processes
3.9.2.4. Cell Culture Systems for Production of Viral Vectors
3.9.2.5. Serum-Containing versus Serum-Free Media
3.9.3. Bioprocessing of Viral Vectors
3.9.3.1. AAV Vector Production
3.9.3.2. Adenoviral Vector Production
3.9.3.3. Lentiviral Vector Production
3.9.3.4. γ -Retroviral Vector Production
3.9.4. Key Challenges Associated with Vector Manufacturing
3.10. Future Perspectives
4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Product Manufactured
4.2.5. Analysis by Location of Vector Manufacturing Facilities
4.2.6. Analysis by Type of Manufacturer
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Location of Headquarters and Scale of Operation
4.2.9. Analysis by Type of Vector Manufactured
4.2.10. Analysis by Scale of Operation and Type of Vector Manufactured
4.2.11. Analysis by Application Area
4.2.12. Information on Production Capacity
5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Heat Map: Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Type of Product Manufactured
5.2.6. Analysis by Location of Plasmid DNA Manufacturing Facilities
5.2.7. Analysis by Type of Manufacturer
5.2.8. Analysis by Scale of Operation
5.2.9. Analysis by Application Area
5.2.10. Information on Production Capacity
6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Location of Vector Manufacturing Facilities
6.2.3. Analysis by Type of Manufacturer
6.2.4. Analysis by Scale of Operation
6.2.5. Analysis by Type of Vector Manufactured
6.2.6. Analysis by Scale of Operation and Type of Vector Manufactured
6.2.7. Analysis by Application Area
7. VECTOR AND GENE THERAPY MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Vector and Gene Therapy Manufacturing Technologies
7.2.1. Analysis by Type of Technology
7.2.2. Analysis by Purpose of Technology
7.2.3. Analysis by Scale of Operation
7.2.4. Analysis by Type of Vector
7.2.5. Analysis by Application Area
7.2.6. Most Active Players: Analysis by Number of Technology
7.3. Concluding Remarks
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Vector and Gene Therapy: In-House Manufacturers
8.3.1. Players based in North America
8.3.2. Players based in Europe
8.3.3. Players based in Asia-Pacific and Rest of the World
8.4. Vector and Gene Therapy: Contract Manufacturing Organizations
8.4.1. Players based in North America
8.4.2. Players based in Europe
8.4.3. Players based in Asia-Pacific and Rest of the World
8.5. Vector and Gene Therapy: Players Engaged in In-house and Contract Manufacturing
8.5.1. Players based in North America
8.5.2. Players based in Europe
8.5.3. Players based in Asia-Pacific and Rest of the World
9. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
9.1. Chapter Overview
9.2. Advanced BioScience Laboratories
9.2.1. Company Overview
9.2.2. Manufacturing Facilities
9.2.3. Recent Developments and Future Outlook
9.3. Aldevron
9.3.1. Company Overview
9.3.2. Financial Information
9.3.3. Manufacturing Facilities
9.3.4. Manufacturing Experience
9.3.5. Recent Developments and Future Outlook
9.4. BioReliance / SAFC Commercial (Merck KGaA)
9.4.1. Company Overview
9.4.2. Financial Information
9.4.3. Vector Manufacturing Technology Portfolio
9.4.4. Manufacturing Facilities
9.4.5. Recent Developments and Future Outlook
9.5. bluebird bio
9.5.1. Company Overview
9.5.2. Financial Information
9.5.3. Manufacturing Facilities
9.5.4. Manufacturing Experience
9.5.5. Recent Development and Future Outlook
9.6. Other Companies
9.6.1. Audentes Therapeutics
9.6.1.1. Company Overview
9.6.1.2. Financial Information
9.6.1.3. Manufacturing Facilities
9.6.1.4. Recent Developments and Future Outlook
9.6.2. Emergent BioSolutions
9.6.2.1. Company Overview
9.6.2.2. Financial Information
9.6.2.3 Manufacturing Facilities
9.6.2.4. Recent Developments and Future Outlook
9.6.3. FUJIFILM Diosynth Biotechnologies
9.6.3.1. Company Overview
9.6.3.2. Financial Information
9.6.3.3. Manufacturing Facilities
9.6.3.4. Manufacturing Experience
9.6.3.5. Recent Developments and Future Outlook
9.6.4. MeiraGTx
9.6.4.1. Company Overview
9.6.4.2. Manufacturing Facilities
9.6.4.3. Recent Developments and Future Outlook
9.6.5. Spark Therapeutics
9.6.5.1. Company Overview
9.6.5.2. Financial Information
9.6.5.3. Manufacturing Facilities
9.6.5.4. Vector Manufacturing Technology Portfolio
9.6.5.5. Manufacturing Experience
9.6.5.6. Recent Developments and Future Outlook
9.6.7. Vigene Biosciences
9.6.7.1. Company Overview
9.6.7.2. Manufacturing Facilities
9.6.7.3. Vector Manufacturing Technology Portfolio
9.6.7.4. Manufacturing Experience
9.6.7.5. Recent Developments and Future Outlook
10. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
10.1. Chapter Overview
10.2. Biovian
10.2.1. Company Overview
10.2.2. Manufacturing Facilities
10.2.3. Recent Developments and Future Outlook
10.3. Centre for Process Innovation
10.3.1. Company Overview
10.3.2. Manufacturing Facilities
10.3.3. Recent Developments and Future Outlook
10.4. Cobra Biologics
10.4.1. Company Overview
10.4.2. Financial Information
10.4.3. Manufacturing Facilities
10.4.4. Vector Manufacturing Technology Portfolio
10.4.5. Manufacturing Experience
10.4.6. Recent Developments and Future Outlook
10.5. FinVector
10.5.1. Company Overview
10.5.2. Manufacturing Facilities
10.5.3. Vector Manufacturing Technology Portfolio
10.5.4. Manufacturing Experience
10.5.5. Recent Developments and Future Outlook
10.6. Kaneka Eurogentec
10.6.1. Company Overview
10.6.2. Manufacturing Facilities
10.6.3. Manufacturing Experience
10.6.4. Recent Developments and Future Outlook
10.7. Lonza
10.7.1. Company Overview
10.7.2. Financial Information
10.7.3. Vector Manufacturing Technology Portfolio
10.7.4. Manufacturing Facilities
10.7.5. Recent Developments and Future Outlook
10.8. MolMed
10.8.1. Company Overview
10.8.2. Financial Information
10.8.3. Manufacturing Facilities
10.8.4. Recent Developments and Future Outlook
10.9. Novasep
10.9.1. Company Overview
10.9.2. Financial Information
10.9.3. Manufacturing Facilities
10.9.4. Manufacturing Experience
10.9.5. Recent Developments and Future Outlook
10.10. Orchard Therapeutics
10.10.1. Company Overview
10.10.2. Manufacturing Facilities
10.10.3 Recent Developments and Future Outlook
10.11. Oxford BioMedica
10.11.1. Company Overview
10.11.2. Financial Information
10.11.3. Manufacturing Facilities
10.11.4. Vector Manufacturing Technology Portfolio
10.11.5. Manufacturing Experience
10.11.6. Recent Developments and Future Outlook
10.12. Richter-Helm
10.12.1. Company Overview
10.12.2. Manufacturing Facilities
10.12.3. Recent Developments and Future Outlook
10.13. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
10.13.1. Company Overview
10.13.2. Financial Information
10.13.3. Manufacturing Facilities
10.13.4. Recent Developments and Future Outlook
10.14. uniQure
10.14.1. Company Overview
10.14.2. Financial Information
10.14.3. Manufacturing Facilities
10.14.4. Vector Manufacturing Technology Portfolio
10.14.5. Recent Developments and Future Outlook
10.15. Vibalogics
10.15.1. Company Overview
10.15.2. Manufacturing Facilities
10.15.3. Recent Developments and Future Outlook
10.16. VIVEbiotech
10.16.1. Company Overview
10.16.2. Vector Manufacturing Technology Portfolio
10.16.3. Manufacturing Facilities
10.16.4. Recent Developments and Future Outlook
10.17. Other Companies
10.17.1. Cell and Gene Therapy Catapult
10.17.1.1. Company Overview
10.17.1.2. Manufacturing Facilities
10.17.1.3. Recent Developments and Future Outlook
11. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
11.1. Chapter Overview
11.2. Wuxi AppTec
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Manufacturing Facilities
11.2.4. Manufacturing Experience
11.2.5. Recent Developments and Future Outlook
11.3. Other Key Players
12. OTHER KEY PLAYERS
12.1. Chapter Overview
12.2. Thermo Fisher Scientific
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Vector Manufacturing Related Capabilities
12.2.4. Recent Developments and Future Outlook
12.3. BioNTech Innovative Manufacturing
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Vector Manufacturing Related Capabilities
12.3.4. Recent Developments and Future Outlook
12.3. Celonic
12.3.1. Company Overview
12.3.2. Vector Manufacturing Related Capabilities
12.3.3. Recent Developments and Future Outlook
13. RECENT PARTNERSHIPS
13.1. Chapter Overview
13.2. Partnership Models
13.3. Vector and Gene Therapy Manufacturing: Recent Partnerships
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Scale of Operation
13.3.4. Analysis by Type of Vector
13.3.5. Analysis by Therapeutic Area
13.3.6. Most Active Players: Analysis by Number of Partnerships
13.3.7. Geographical Analysis
13.3.7.1. Intercontinental and Intracontinental Agreements
13.4. Other Collaborations
14. RECENT EXPANSIONS
14.1. Chapter Overview
14.2. Expansions Models
14.3. Vector and Gene Therapy Manufacturing: Recent Expansions
14.3.1. Analysis by Year of Expansion
14.3.2. Analysis by Type of Expansion
14.3.3. Analysis by Amount Invested by Key Players
14.3.4. Analysis by Scale of Operation
14.3.5. Analysis by Type of Vector
14.3.6. Analysis by Application Area
14.3.7. Most Active Players: Analysis by Number of Expansions
14.3.8. Geographical Analysis
14.3.8.1. Analysis by Location of Expansion
15. STRATEGIC PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Strategic Partner Analysis: Viral Vector based Therapy Developers
15.3. Methodology and Key Parameters
15.3.1. Opportunities for AAV Vector- based Therapy Developers
15.3.1.1. Most Likely Partners
15.3.1.2. Likely Partners
15.3.1.3. Less Likely Partners
15.3.1.4. Least Likely Partners
15.3.2. Opportunities for Adenoviral Vector based Therapy Developers
15.3.2.1. Most Likely Partners
15.3.2.2. Likely Partners
15.3.2.3. Less Likely Partners
15.3.2.4. Least Likely Partners
15.3.3. Opportunities for Lentiviral Vector based Therapy Developers
15.3.3.1. Most Likely Partners
15.3.3.2. Likely Partners
15.3.3.3. Less Likely Partners
15.3.3.4. Least Likely Partners
15.3.4. Opportunities for Retroviral Vector based Therapy Developers
15.3.4.1. Most Likely Partners
15.3.4.2. Likely Partners
15.3.4.3. Less Likely Partners
15.3.4.4. Least Likely Partners
15.3.5. Opportunities for Other Viral Vector based Therapy Developers
15.3.5.1. Most Likely Partners
15.3.5.2. Likely Partners
15.3.5.3. Less Likely Partners
15.3.5.4. Least Likely Partners
15.4. Strategic Partner Analysis: Viral Vector based Purification Product Developers
15.5. Methodology and Key Parameters
15.5.1. Opportunities for AAV based Purification Product Developers
15.5.1.1. Most Likely Partners
15.5.1.2. Likely Partners
15.5.2. Opportunities for Adenoviral Vector based Purification Product Developers
15.5.2.1. Most Likely Partners
15.5.2.2. Likely Partners
15.5.3. Opportunities for Lentiviral Vector based Purification Product Developers
15.5.3.1. Most Likely Partners
15.5.3.2. Likely Partners
15.5.4. Opportunities for Retroviral Vector based Purification Product Developers
15.5.4.1. Most Likely Partners
15.5.4.2. Likely Partners
15.5.5. Opportunities for Other Viral Vector based Purification Product Developers
15.5.5.1. Most Likely Partners
15.5.5.2. Likely Partners
16. EMERGING VECTORS
16.1. Chapter Overview
16.1.1. Alphavirus based Vectors
16.1.2. Anc80 based Vectors
16.1.3. Bifidobacterium longum based Vectors
16.1.4. Cytomegalovirus based Vectors
16.1.5. Listeria monocytogenes based Vectors
16.1.6. Minicircle DNA based Vectors
16.1.7. Myxoma Virus based Vectors
16.1.8. Self-Complementary Vectors
16.1.9. Sendai Virus based Vectors
16.1.10. Sleeping Beauty Transposons
16.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors
16.1.12. Chimeric Viral Vectors
17. KEY INSIGHTS
17.1. Chapter Overview
17.2. Vector and Gene Therapy Manufacturers: Analysis by Purpose of Manufacturing, Type of Vector Manufactured and Scale of Operation
17.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size and Type of Vector Manufactured
17.4. Vector and Gene Therapy Manufacturers: Prominent Geographical Hubs by Type of Organization
17.4.1. Contract Manufacturing Organizations
17.4.2. In-House Manufacturers
17.5. Vector and Gene Therapy Manufacturers: Analysis by Location of Manufacturing Facilities and Type of Vector Manufactured
17.5.1. AAV Vector Manufacturers
17.5.2. Adenoviral Vector Manufacturers
17.5.3. Lentiviral Vector Manufacturers
17.5.4. Retroviral Vector Manufacturers
17.5.5. Plasmid DNA Manufacturers
18. COST PRICE ANALYSIS
18.1. Chapter Overview
18.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
18.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models
18.3.1. Pricing Models on the Basis of Expert Opinions
18.3.2. Pricing Models on the Basis of Manufacturing Cost
18.3.2.1. Pricing Models on the Basis of Technology Used
18.3.2.2. Pricing Models on the Basis of Scale of Manufacturing
18.3.2.3. Pricing Models on the Basis of Type of Client
18.3.3. Prices of Different Types of Vectors
18.4. Concluding Remarks
19. CAPACITY ANALYSIS
19.1. Chapter Overview
19.2. Methodology and Key Assumptions
19.2. Global Installed Viral Vector and Gene Therapy Manufacturing Capacity
19.3. Global Installed Viral Vector Manufacturing Capacity
19.3.1. Analysis by Company Size
19.3.2. Analysis by Scale of Operation
19.3.3. Analysis by Location of Manufacturing Facilities
19.4. Global Installed Plasmid DNA Manufacturing Capacity
19.4.1. Analysis by Company Size
19.4.2. Analysis by Scale of Operation
19.4.3. Analysis by Location of Manufacturing Facilities
19.4. Concluding Remarks
20. DEMAND ANALYSIS
20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Global Clinical Demand for Viral Vectors and Plasmid DNA, 2022-2035
20.3.1. Analysis by Type of Vector
20.3.2. Analysis by Type of Therapy
20.3.3. Analysis by Therapeutic Area
20.3.4. Analysis by Geographical Location
20.4. Global Commercial Demand for Viral Vectors and Plasmid DNA, 2022-2035
20.4.1. Analysis by Type of Vector
20.4.2. Analysis by Type of Therapy
20.4.3. Analysis by Therapeutic Area
20.4.4. Analysis by Geographical Location
20.5. Demand and Supply Analysis
20.5.1. Scenario 1
20.5.2. Scenario 2
20.5.3. Scenario 3
21. MARKET SIZING AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Scope of the Forecast
21.3. Forecast Methodology
21.4. Input Tables and Key Assumptions
21.5. Global Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035
21.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Type of Vector Manufactured
21.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Market Attractiveness by Purpose of Manufacturing
21.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Scale of Operation
21.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Type of Vector Manufactured
21.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Therapeutic Area
21.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Application Area
21.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Key Geographical Regions
21.6. Current and Future Market Opportunity for Commercial Products
21.6.1. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Type of Vector Manufactured
21.6.1.1. AAV Vectors
21.6.1.1.1. AAV Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.1.2. AAV Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.1.3. AAV Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.2. Adenoviral Vectors
21.6.1.2.1. Adenoviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.2.2. Adenoviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.2.3. Adenoviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.3. Lentiviral Vectors
21.6.1.3.1. Lentiviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.3.2. Lentiviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.4. Retroviral Vectors
21.6.1.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.5. Plasmid DNA
21.6.1.5.1. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.5.2. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.5.3. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.2. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.3. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.4. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.7. Current and Future Market Opportunity for Clinical Candidates
21.7.1. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Type of Vector Manufactured
21.7.2.1. AAV Vectors
21.7.2.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.1.2. AAV Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.1.3. AAV Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.2. Adenoviral Vectors
21.7.2.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.3. Lentiviral Vectors
21.7.2.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.4. Retroviral Vectors
21.7.2.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.5. Plasmid DNA
21.7.2.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.3. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.4. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8. Current and Future Market Opportunity from Preclinical Candidates
21.8.1. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Vector Manufactured
21.8.1.1. AAV Vectors
21.8.1.1.1. AAV Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.1.2. AAV Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.1.3. AAV Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.2. Adenoviral Vectors
21.8.1.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.3. Lentiviral Vectors
21.8.1.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.4. Retroviral Vectors
21.8.1.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.5. Plasmid DNA
21.8.1.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.5.2. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.5.3. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.2. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.3. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Therapeutic Area
21.8.4. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.5. Viral Vector and Plasmid DNA Manufacturing Market for preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.9 Current and Future Market opportunity from Vector-Based Vaccines
21.9.1. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Scale of Operation
21.9.2. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Type of Vector Manufactured
21.9.3. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Therapeutic Area
21.9.4. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Key Geographical Regions
22. PORTER’S FIVE FORCES ANALYSIS
22.1 Chapter Overview
22.2. Methodology and Assumptions
22.2.1. Key Parameters
22.2.2. Threats of New Entrants
22.2.3. Bargaining Power of Suppliers
22.2.4. Threats of Substitute Products
22.2.5. Rivalry Among Existing Competitors
22.3. Concluding Remarks
23. KEY DRIVERS AND CHALLENGES
23.1. Chapter Overview
23.2. Viral Vector and Plasmid DNA Manufacturing Market: Key Drivers and Challenges
23.2.1. AAV Vectors
23.2.2. Adenoviral Vectors
23.2.3. Lentiviral Vectors
23.2.4. Retroviral Vectors
23.2.5. Plasmid DNA
23.3. Concluding Remarks
24. SURVEY ANALYSIS
24.1. Chapter Overview
24.2. Analysis by Seniority Level of Respondents
24.3. Analysis by Type of Manufacturer
24.4. Analysis by Scale of Operation
24.5. Analysis by Type of Vector Manufactured
25. CONCLUDING REMARKS
26. EXECUTIVE INSIGHTS
26.1. Chapter Overview
26.2. Batavia Biosciences
26.2.1. Company Snapshot
26.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and President
26.3. CEVEC Pharmaceuticals
26.3.1. Company Snapshot
26.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer
26.4. Vigene Biosciences
26.4.1. Company Snapshot
26.4.2. Interview Transcript: Jeffrey Hung, Former Chief Commercial Officer
26.5. Delphi Genetics
26.5.1. Company Snapshot
26.5.2. Interview Transcript: Cedric Szpirer, Former Executive and Scientific Director
26.6. Clean Cells
26.6.1. Company Snapshot
26.6.2. Interview Transcript: Olivier Boisteau, Strategy Direction and Executive Board Member, Laurent Ciavatti, Former Business Development Manager and Xavier Leclerc, Head of Gene Therapy
26.7. Novasep
26.7.1. Company Snapshot
26.7.2. Interview Transcript: Alain Lamproye, Former President of Biopharma Business Unit
26.8. Amsterdam BioTherapeutics Unit (AmBTU)
26.8.1. Organization Snapshot
26.8.2. Interview Transcript: Joost van den Berg, Former Director
26.9. MGH Viral Vector Development Facility, Massachusetts General Hospital
26.9.1. Organization Snapshot
26.9.2. Interview Transcript: Bakhos Tannous, Director
26.10. Translational Vector Core, University of Nantes
26.10.1. Organization Snapshot
26.10.2. Interview Transcript: Eduard Ayuso, DVM, PhD, Scientific Director
26.11. CJ PARTNERS
26.11.1. Company Snapshot
26.11.2. Interview Transcript: Colin Lee Novick, Managing Director
26.12. ACGT
26.12.1. Company Snapshot
26.12.2. Interview Transcript: Semyon Rubinchik, Scientific Director
26.13. Richter-Helm
26.13.1. Company Snapshot
26.13.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development
26.14. Plasmid Factory
26.14.1. Company Snapshot
26.14.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Former Marketing Manager
26.15. Waisman Biomanufacturing
26.15.1. Company Snapshot
26.15.2. Interview Transcript: Brian M Dattilo, Business Development Manager
26.16. EFS-West Biotherapy
26.16.1. Company Snapshot
26.16.2. Interview Transcript: Beatrice Araud, ATMP Key Account Manager
26.17. GEG Tech
26.17.1. Company Snapshot
26.17.2. Interview Transcript: Nicolas Grandchamp, R&D Leader
26.18. Polypus Transfection
26.18.1. Company Snapshot
26.18.2. Interview Transcript: Géraldine Guérin-Peyrou, Director of Marketing and Technical Support
26.19. Vive Biotech
26.19.1. Company Snapshot
26.19.2. Interview Transcript: Naiara Tejados, Head of Marketing and Technology Development
26.20. Independent Consultant
26.20.1. Interview Transcript: Jeffery Hung
27. APPENDIX I: TABULATED DATA
28. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 3.2 Vector Production: Types of Manufacturers
Figure 3.3 Viral Vectors: Manufacturing Process
Figure 4.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Figure 4.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 4.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Figure 4.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Country-wise)
Figure 4.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer and Company Size
Figure 4.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 4.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Figure 4.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 5.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Figure 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Figure 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 5.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Figure 5.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Figure 5.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 5.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 5.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 6.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Figure 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Figure 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Figure 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer and Location of Vector Manufacturing Facilities
Figure 6.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Figure 6.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 6.7 Logo Landscape: Distribution by Scale of Operation and Type of Vector Manufactured
Figure 6.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 7.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 7.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 7.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Figure 7.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Figure 7.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 7.6 Most Active Players: Distribution by Number of Technology
Figure 8.1 Company Competitiveness Analysis: Distribution of Players based in North America (In-House Manufacturers)
Figure 8.2 Company Competitiveness Analysis: Distribution of Players based in Europe (In-House Manufacturers)
Figure 8.3 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (In-House Manufacturers)
Figure 8.4 Company Competitiveness Analysis: Distribution of Players based in North America (Contract Manufacturing Organizations)
Figure 8.5 Company Competitiveness Analysis: Distribution of Players based in Europe (Contract Manufacturing Organizations)
Figure 8.6 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Contract Manufacturing Organizations)
Figure 8.7 Company Competitiveness Analysis: Distribution of Players based in North America (Both In-House and Contract Manufacturing Organizations)
Figure 8.8 Company Competitiveness Analysis: Distribution of Players based in Europe (Both In-House and Contract Manufacturing Organizations)
Figure 8.9 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Both In-House and Contract Manufacturing Organizations)
Figure 9.1 Danaher: Annual Revenues, 2014 - Q1 2022 (USD Billion)
Figure 9.2 Merck KGaA: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Figure 9.3 H.A.V.E.: AAV Vector Manufacturing Technology
Figure 9.4 bluebird bio: Annual Revenues, 2014 – Q1 2022 (USD Million)
Figure 9.5 Astellas Pharma: Annual Revenues, 2014 – 2021 (JPY Billion)
Figure 9.6 Emergent BioSolutions: Annual Revenues, 2014 – 2021 (USD Million)
Figure 9.7 FUJIFILM Holdings: Annual Revenues, 2013 - H1 FY 2021 (JPY Billion)
Figure 9.8 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Figure 9.8 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Figure 10.1 Charles River Laboratories: Annual Revenues, 2017 - Q1 2022 (USD Billion)
Figure 10.2 Lonza: Annual Revenues, 2014 - 2021 (CHF Billion)
Figure 10.3 AGC Biologics: Annual Revenues, 2020 – 2022 (JPY Billion)
Figure 10.4 Novasep: Viral Vector Manufacturing Process
Figure 10.5 Oxford BioMedica: Annual Revenues, 2014 - 2021 (GBP Million)
Figure 10.6 Sanofi: Annual Revenues, 2014 – Q1 2022 (EUR Billion)
Figure 10.7 uniQure: Annual Revenues, 2014 - Q1 2022 (USD Million)
Figure 11.1 Wuxi AppTec: Annual Revenues, 2017 - H1 2022 (RMB Million)
Figure 12.1 Thermo Fisher Scientific: Annual Revenues, 2017-Q1 2022 (USD Billion)
Figure 12.2 BioNTech Innovative Manufacturing: Annual Revenues, 2017-Q1 2022 (EUR Billion)
Figure 13.1 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2022
Figure 13.2 Recent Partnerships: Distribution by Type of Partnership
Figure 13.3 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2022
Figure 13.4 Recent Partnerships: Distribution by Scale of Operation
Figure 13.5 Recent Partnerships: Distribution by Type of Vector(s)
Figure 13.6 Recent Partnerships: Distribution by Therapeutic Area
Figure 13.7 Most Active Players: Distribution by Number of Partnerships
Figure 13.8 Recent Partnerships: Geographical Analysis
Figure 13.9 Recent Partnerships: Intercontinental and Intracontinental Agreements
Figure 14.1 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2022
Figure 14.2 Recent Expansions: Distribution by Type of Expansion, 2015 - 2022
Figure 14.3 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2022
Figure 14.4 Recent Expansions: Distribution of Amount Invested by Key Players
Figure 14.5 Recent Expansions: Distribution by Scale of Operation
Figure 14.6 Recent Expansions: Distribution by Type of Vector(s)
Figure 14.7 Recent Expansions: Distribution by Application Area
Figure 14.8 Most Active Players: Distribution by Number of Expansions
Figure 14.9 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 14.10 Recent Expansions: Distribution by Location of Expansion Project
Figure 17.1 Vector and Gene Therapy Manufacturers: Competitive Landscape by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Figure 17.2 Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of Vector Manufactured
Figure 17.3 Vector and Gene Therapy Contract Manufacturers: Distribution by Prominent Geographical Hubs
Figure 17.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Prominent Geographical Hubs
Figure 17.5 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.6 Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.7 Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.8 Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.9 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 18.1 Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 19.1 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Figure 19.2 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Figure 19.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 19.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 19.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 19.6 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 19.7 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of operation (in Liters)
Figure 19.8 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Figure 19.9 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 19.10 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 19.11 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of operation
Figure 19.12 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Figure 20.1 Global Clinical Demand for Viral Vector and Plasmid DNA, 2022-2035 (Thousand Patients)
Figure 20.2 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 20.3 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 20.4 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 20.5 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 20.6 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Figure 20.7 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 20.8 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 20.9 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 20.10 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 20.11 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2022-2035
Figure 20.12 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2022-2035
Figure 20.13 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2022-2035
Figure 21.1 Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035 (USD Million)
Figure 21.2 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.3 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2022-2035
Figure 20.4 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.5 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Figure 20.6 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 20.7 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Manufacturer, 2022-2035 (USD Million)
Figure 20.8 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.9 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.10 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Figure 20.11 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Figure 20.12 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2022, 2028 and 2035 (USD Million)
Figure 20.13 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.14 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 20.15 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.16 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.17 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 20.18 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.19 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.20 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.21 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.22 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.23 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.24 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.25 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.26 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.27 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.28 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.29 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.30 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Figure 21.31 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.32 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.33 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.34 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.35 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.36 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.37 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.38 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.39 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.40 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.41 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.42 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.43 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.44 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.45 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.46 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.47 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.48 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2022, 2025 and 2035 (USD Million)
Figure 21.49 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Animal Model Used, 2022-2035 (USD Million)
Figure 21.50 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022, 2025 and 2035 (USD Million)
Figure 21.51 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.52 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.53 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.54 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.55 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.56 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.57 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.58 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.59 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.60 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.61 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.62 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.63 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.64 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.65 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.66 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.67 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.68 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 21.69 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.70 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 22.1 Porter’s Five Forces
Figure 22.2 Porter’s Five Forces: Harvey Ball Analysis
Figure 23.1 Key Drivers and Challenges: AAV Vectors
Figure 23.2 Key Drivers and Challenges: Adenoviral Vectors
Figure 23.3 Key Drivers and Challenges: Lentiviral Vectors
Figure 23.4 Key Drivers and Challenges: Retroviral Vectors
Figure 23.5 Key Drivers and Challenges: Plasmid DNA
Figure 24.1 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 24.2 Survey Analysis: Distribution by Scale of operation
Figure 24.3 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 25.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Viral Vectors
Figure 25.2 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Plasmid DNA
Figure 25.3 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Non-Industry Players
Figure 25.4 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Vector and Gene Therapy manufacturing Technologies
Figure 25.5 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Recent Expansions and Partnerships
Figure 25.6 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Strategic Partner Analysis
Figure 25.7 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Capacity Analysis
Figure 25.8 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Demand Analysis
Figure 25.9 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Market Forecast and Opportunity Analysis
Table 3.1 Key Features of Viral Vectors
Table 3.2 Key Features of Small-scale Cell Culture Systems
Table 4.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Viral Vector Manufacturing Facilities, Scale of operation and Type of Manufacturer
Table 4.3 Heat Map: Information on Location of Headquarters and Scale of operation
Table 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector Manufactured
Table 4.5 Heat Map: Information on Scale of operation and Type of Viral Vector Manufactured
Table 4.6. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 4.7. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 5.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Company Size and Location of Headquarters
Table 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facilities, Scale of operation and Type of Manufacturer
Table 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 6.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of operation
Table 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 7.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 9.1 Vector and Gene Therapy Production in North America: List of Profiled Companies
Table 9.2 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 9.3 Aldevron Plasmid DNA: QC Assays
Table 9.4 Aldevron: Recent Developments and Future Outlook
Table 9.5 Audentes Therapeutics: Recent Developments and Future Outlook
Table 9.6 BioReliance / SAFC Commercial (Merck KGaA): Recent Developments and Future Outlook
Table 9.7 bluebird bio: Recent Developments and Future Outlook
Table 9.8 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 9.10 MeiraGTx: Recent Developments and Future Outlook
Table 9.11 MassBiologics: Recent Developments and Future Outlook
Table 9.12 Spark Therapeutics: Recent Developments and Future Outlook
Table 9.13 Vigene Biosciences: Recent Developments and Future Outlook
Table 10.1 Vector and Gene Therapy Production in Europe: List of Players Profiled
Table 10.2 Biovian: Recent Developments and Future Outlook
Table 10.3 Centre for Process Innovation: Recent Developments and Future Outlook
Table 10.4 Cobra Biologics: Recent Developments and Future Outlook
Table 10.5 FinVector: Recent Developments and Future Outlook
Table 10.6 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 10.7 Lonza: Recent Developments and Future Outlook
Table 10.8 MolMed: Recent Developments and Future Outlook
Table 10.9 Novasep: Manufacturing Experience
Table 10.10 Novasep: Recent Developments Future Outlook
Table 10.11 Orchard Therapeutics: Recent Developments Future Outlook
Table 10.12 Oxford BioMedica: Recent Developments and Future Outlook
Table 10.13 Richter-Helm: Recent Developments and Future Outlook
Table 10.14 Sanofi: Recent Developments and Future Outlook
Table 10.15 uniQure: Recent Developments and Future Outlook
Table 10.16 Vibalogics: Recent Developments and Future Outlook
Table 10.17 VIVEbiotech: Recent Developments and Future Outlook
Table 10.18 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 11.1 Wuxi AppTec: Recent Developments and Future Outlook
Table 11.2 List of Other Key Players Based in Asia Pacific
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Partnerships, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships, 2015-2020 (till September)
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: Information on Scale of operation, Type of Vector Manufactured and Application Area, 2015-2020 (till September)
Table 13.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 15.2 AAV Vector-based Therapy Developers: Likely Partners
Table 15.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 15.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 15.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 15.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 15.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 15.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 15.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 15.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 15.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 15.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 15.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 15.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 15.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 15.16 Retroviral Vector-based Therapy Developers: Least Likely Partners
Table 15.17 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 15.18 Other Viral Vector-based Therapy Developers: Likely Partners
Table 15.19 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 15.20 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 15.21 AAV Vector Purification Product Developers: Most Likely Partners
Table 15.22 AAV Vector Purification Product Developers: Likely Partners
Table 15.23 Adenoviral Vector Purification Product Developers: Most Likely Partners
Table 15.24 Adenoviral Vector Purification Product Developers: Likely Partners
Table 15.25 Lentiviral Vector Purification Product Developers: Most Likely Partners
Table 15.26 Lentiviral Vector Purification Product Developers: Likely Partners
Table 15.27 Retroviral Vector Purification Product Developers: Most Likely Partners
Table 15.28 Retroviral Vector Purification Product Developers: Likely Partners
Table 15.29 Other Viral Vector Purification Product Developers: Most Likely Partners
Table 15.30 Other Viral Vector Purification Product Developers: Likely Partners
Table 18.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 18.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 19.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 19.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 19.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 19.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 20.1. Global Viral Vectors Manufacturing Annual Demand, 2022-2035 (1020 vg)
Table 20.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2022-2035 (1020 vg)
Table 20.3 Global Viral Vector Manufacturing: Annual Supply (Scenario 2), 2022-2035 (1020 vg)
Table 20.4 Global Viral Vector Manufacturing: Annual Supply (Scenario 3), 2022-2035 (1020 vg)
Table 21.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 21.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 21.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2022-2035
Table 21.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2022-2035
Table 21.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 24.1 Survey Response: Overview of the Participating Companies / Organizations
Table 24.2 Survey Response: Seniority Level of Respondents
Table 24.3 Survey Response: Type of Vector
Table 24.4 Survey Response: Scale of operation
Table 24.5 Survey Response: Vector Stabilization Technology
Table 24.6 Survey Response: Type of Manufacturer (In-house Production versus Contract Services)
Table 26.1 Batavia Biosciences: Key Highlights
Table 26.2 CEVEC Pharmaceuticals: Key Highlights
Table 26.3 Vigene Biosciences: Key Highlights
Table 26.4 Delphi Genetics: Key Highlights
Table 26.5 Clean Cells: Key Highlights
Table 26.6 Novasep: Key Highlights
Table 26.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 26.8 MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 26.9 Translational Vector Core, University of Nantes: Key Highlights
Table 26.10 CJ PARTNERS: Key Highlights
Table 26.11 ACGT: Key Highlights
Table 26.12 Richter-Helm: Key Highlights
Table 26.13 Plasmid Factory: Key Highlights
Table 26.14 Waisman Biomanufacturing: Key Highlights
Table 26.15 EFS-West Biotherapy: Key Highlights
Table 26.16 GEG Tech: Key Highlights
Table 27.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 27.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 27.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Table 27.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Table 27.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 27.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Table 27.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Country-wise)
Table 27.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer and Company Size
Table 27.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 27.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 27.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 27.12 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 27.13 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 27.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Table 27.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Table 27.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 27.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Table 27.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Table 27.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 27.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 27.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 27.22 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Table 27.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Table 27.24 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Table 27.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer and Location of Vector Manufacturing Facilities
Table 27.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Table 27.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 27.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 27.29 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 27.30 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 27.31 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Table 27.32 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Table 27.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 27.34 Most Active Players: Distribution by Number of Technology
Table 27.35 Danaher: Annual Revenues, 2014 - Q1 2022 (USD Billion)
Table 27.36 Merck KGaA: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Table 27.37 bluebird bio: Annual Revenues, 2014 – Q1 2022 (USD Million)
Table 27.38 Astellas Pharma: Annual Revenues, 2014 – 2021 (JPY Billion)
Table 27.39 Emergent BioSolutions: Annual Revenues, 2014 – 2021 (USD Million)
Table 27.40 FUJIFILM Holdings: Annual Revenues, 2013 - H1 FY 2021 (JPY Billion)
Table 27.41 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Table 27.42 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Table 27.43 Charles River Laboratories: Annual Revenues, 2017 - Q1 2022 (USD Billion)
Table 27.44 Lonza: Annual Revenues, 2014 - 2021 (CHF Billion)
Table 27.45 AGC Biologics: Annual Revenues, 2020 – 2022 (JPY Billion)
Table 27.46 Oxford BioMedica: Annual Revenues, 2014 - 2021 (GBP Million)
Table 27.47 Sanofi: Annual Revenues, 2014 – Q1 2022 (EUR Billion)
Table 27.48 uniQure: Annual Revenues, 2014 - Q1 2022 (USD Million)
Table 27.49 Wuxi AppTec: Annual Revenues, 2017 - H1 2022 (RMB Million)
Table 27.50 Thermo Fisher Scientific: Annual Revenues, 2017-Q1 2022 (USD Billion)
Table 27.51 BioNTech Innovative Manufacturing: Annual Revenues, 2017-Q1 2022 (EUR Billion)
Table 27.52 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2022
Table 27.53 Recent Partnerships: Distribution by Type of Partnership
Table 27.54 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2022
Table 27.55 Recent Partnerships: Distribution by Scale of Operation
Table 27.56 Recent Partnerships: Distribution by Type of Vector(s)
Table 27.57 Recent Partnerships: Distribution by Therapeutic Area
Table 27.58 Most Active Players: Distribution by Number of Partnerships
Table 27.59 Recent Partnerships: Geographical Analysis
Table 27.60 Recent Partnerships: Intercontinental and Intracontinental Agreements
Table 27.61 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2022
Table 27.62 Recent Expansions: Distribution by Type of Expansion, 2015 - 2022
Table 27.63 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2022
Table 27.64 Recent Expansions: Distribution of Amount Invested by Key Players
Table 27.65 Recent Expansions: Distribution by Scale of Operation
Table 27.66 Recent Expansions: Distribution by Type of Vector(s)
Table 27.67 Recent Expansions: Distribution by Application Area
Table 27.68 Most Active Players: Distribution by Number of Expansions
Table 27.69 Recent Expansions: Intercontinental and Intracontinental Expansions
Table 27.70 Recent Expansions: Distribution by Location of Expansion Project
Table 27.71 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Table 27.72 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Table 27.73 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 27.74 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 27.75 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 27.76 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 27.77 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Operation (in Liters)
Table 27.78 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Table 27.79 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 27.80 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 27.81 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale ofOperation
Table 27.82 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Table 27.83 Global Clinical Demand for Viral Vector and Plasmid DNA, 2022-2035 (Thousand Patients)
Table 27.84 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 27.85 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 27.86 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 27.87 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 27.88 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Table 27.89 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 27.90 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 27.91 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 27.92 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 27.93 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2022-2035
Table 27.94 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2022-2035
Table 27.95 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2022-2035
Table 27.96 Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035 (USD Million)
Table 27.97 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.98 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2022-2035
Table 27.99 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.100 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Table 27.101 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 27.102 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Manufacturer, 2022-2035 (USD Million)
Table 27.103 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.104 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.105 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Table 27.106 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Table 27.107 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2022, 2028 and 2035 (USD Million)
Table 27.108 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.109 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.110 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.111 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.112 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.113 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.114 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.115 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.116 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.118 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.119 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.120 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.121 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.122 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.123 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.124 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.125 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.126 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Table 27.127 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.128 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.129 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.130 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.131 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.132 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.133 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.134 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.135 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.136 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.137 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.138 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.139 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.140 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.141 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.142 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.143 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.144 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2022, 2025 and 2035 (USD Million)
Table 27.145 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.146 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022, 2025 and 2035 (USD Million)
Table 27.147 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.148 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.149 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.150 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.151 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.152 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.153 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.154 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.155 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.156 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.157 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.158 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.159 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.160 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.161 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.162 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.163 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.164 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 27.165 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.166 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.167 Survey Analysis: Distribution by Seniority Level of Respondents
Table 27.168 Survey Analysis: Distribution by Scale of operation
Table 27.169 Survey Analysis: Distribution by Type of Vector Manufactured
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES